Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal

Fineline Cube Feb 10, 2026
Company Deals

Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million

Fineline Cube Feb 10, 2026
Company Deals

Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal

Fineline Cube Feb 10, 2026
Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Fineline Cube Feb 10, 2026
Company Deals

Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Deals

Hunan Mabgeek Biotech Files for Hong Kong IPO to Expand Innovative Biologics Pipeline

Fineline Cube Jul 15, 2025

China-based Hunan Mabgeek Biotech Co., Ltd has submitted an application to the Hong Kong Stock...

Company Drug

GSK’s Arexvy RSV Vaccine Expansion for Adults 18-49 Receives FDA Review

Fineline Cube Jul 15, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has...

Others

Dizal’s Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment

Fineline Cube Jul 14, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the inclusion of its sunvozertinib (trade name:...

Company Drug

Boao Super Hospital Introduces Xiaflex for Non-Surgical Peyronie’s Disease Treatment

Fineline Cube Jul 14, 2025

Boao Super Hospital in Hainan last week successfully introduced Xiaflex (collagenase clostridium histolyticum), a nonsurgical...

Company Deals

Lexenpharm Partners with AptarGroup for Single-Dose Nasal Spray Services in Greater China

Fineline Cube Jul 14, 2025

China-based Lexenpharm late last week announced a strategic partnership with Aptar Pharma, a US-based global...

Company Deals Drug

Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development

Fineline Cube Jul 14, 2025

US-based Eolas Therapeutics has entered into an agreement with its UK partner AstraZeneca (AZ, NASDAQ:...

Company Deals

Royal Philips and Suzhou Peixin Collaborate on AI-Powered Interventional Therapy Platform for Structural Heart Disease

Fineline Cube Jul 14, 2025

Dutch device giant Royal Philips (NYSE: PHG) and China-based Suzhou Peixin Technology Co., Ltd. late...

Company Drug

YolTech Therapeutics Receives NMPA Clearance for YOLT-101 in HeFH Clinical Study

Fineline Cube Jul 14, 2025

Shanghai-based YolTech Therapeutics announced that it has received clearance from the National Medical Products Administration...

Company Legal / IP

CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings

Fineline Cube Jul 14, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a favorable outcome in the opposition proceedings...

Others

Eisai Announces Commercial Release of Urece (Dotinurad) from Suzhou Facility in China

Fineline Cube Jul 14, 2025

Japan-based Eisai (TYO: 4523) announced the official commercial release of the first batch of its...

Company Drug

InnoCare Pharma Receives FDA Approval for Mesutoclax in Myeloid Malignancies

Fineline Cube Jul 14, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical trial...

Company Drug

Pfizer and Astellas’ Xtandi Shows Positive Results in Phase III EMBARK Study for Prostate Cancer

Fineline Cube Jul 14, 2025

Partners Pfizer (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced positive topline results from...

Company Drug

Bayer’s Elinzanetant Granted UK Marketing Authorization for Menopause-Related Vasomotor Symptoms

Fineline Cube Jul 11, 2025

Germany’s Bayer (ETR: BAYN) this week announced that the UK Medicines and Healthcare products Regulatory...

Company Deals Drug

AbbVie Licenses IGI Therapeutics’ ISB 2001 for Oncology and Autoimmune Diseases

Fineline Cube Jul 11, 2025

US-based AbbVie (NYSE: ABBV) this week announced a licensing agreement with IGI Therapeutics SA, a...

Company Drug

Jiangsu Jibeier Receives NMPA Approval for Clinical Trials of JJH201601 Liposome in Advanced HNSCC

Fineline Cube Jul 11, 2025

China-based Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566) announced that it has received clinical approval...

Company Drug

Fosun Pharmaceutical Launches Phase III Study for Fumaining in Pediatric Low-Grade Glioma

Fineline Cube Jul 11, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced the initiation of a...

Company Drug

BeOne Medicines’ Tevimbra Approved by European Commission for Nasopharyngeal Carcinoma

Fineline Cube Jul 11, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...

Company Medical Device

Johnson & Johnson MedTech Launches VARIPULSE Platform for Atrial Fibrillation in Asia-Pacific

Fineline Cube Jul 11, 2025

US major Johnson & Johnson MedTech announced the launch of its VARIPULSE Platform in the...

Company Deals

JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca’s Alexion for JUST-AAV Gene Therapy Platform

Fineline Cube Jul 11, 2025

Japan-based JCR Pharmaceuticals Co., Ltd. (TYO: 4552) announced a licensing agreement with UK-based AstraZeneca’s (NASDAQ:...

Company Drug

Zhimeng Biopharma’s CB03-154 Receives CDE Approval for ALS Phase II/III Clinical Study

Fineline Cube Jul 11, 2025

China-based Shanghai Zhimeng Biopharma, Inc. is set to carry out a Phase II/III clinical study...

Posts pagination

1 … 84 85 86 … 622

Recent updates

  • Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal
  • Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million
  • Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal
  • Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million
  • Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal

Company Deals

Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million

Company Deals

Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal

Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.